#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The gut microbiota is an ecological community constituted by a large number of bacteria , archaea , protists , fungi and viruses .
2-1	16-19	The	abstract[3]	new[3]	coref	2-5[4_3]
2-2	20-23	gut	abstract|abstract[3]	new|new[3]	coref	4-10
2-3	24-34	microbiota	abstract[3]	new[3]	_	_
2-4	35-37	is	_	_	_	_
2-5	38-40	an	abstract[4]	giv[4]	coref	3-1[11_4]
2-6	41-51	ecological	abstract[4]	giv[4]	_	_
2-7	52-61	community	abstract[4]	giv[4]	_	_
2-8	62-73	constituted	abstract[4]	giv[4]	_	_
2-9	74-76	by	abstract[4]	giv[4]	_	_
2-10	77-78	a	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-11	79-84	large	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-12	85-91	number	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-13	92-94	of	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-14	95-103	bacteria	abstract[4]|abstract[5]|animal	giv[4]|new[5]|new	coref	8-13[41_0]
2-15	104-105	,	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-16	106-113	archaea	abstract[4]|abstract[5]|animal	giv[4]|new[5]|new	_	_
2-17	114-115	,	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-18	116-124	protists	abstract[4]|abstract[5]|animal	giv[4]|new[5]|new	_	_
2-19	125-126	,	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-20	127-132	fungi	abstract[4]|abstract[5]|animal	giv[4]|new[5]|new	_	_
2-21	133-136	and	abstract[4]|abstract[5]	giv[4]|new[5]	_	_
2-22	137-144	viruses	abstract[4]|abstract[5]|abstract	giv[4]|new[5]|new	_	_
2-23	145-146	.	_	_	_	_

#Text=The microbiota produces multiple metabolites that may cross the intestinal barrier and exert biological effects .
3-1	147-150	The	abstract[11]	giv[11]	coref	4-1[15_11]
3-2	151-161	microbiota	abstract[11]	giv[11]	_	_
3-3	162-170	produces	_	_	_	_
3-4	171-179	multiple	substance[12]	new[12]	_	_
3-5	180-191	metabolites	substance[12]	new[12]	_	_
3-6	192-196	that	substance[12]	new[12]	_	_
3-7	197-200	may	substance[12]	new[12]	_	_
3-8	201-206	cross	substance[12]	new[12]	_	_
3-9	207-210	the	substance[12]|object[13]	new[12]|new[13]	coref	4-9[18_13]
3-10	211-221	intestinal	substance[12]|object[13]	new[12]|new[13]	_	_
3-11	222-229	barrier	substance[12]|object[13]	new[12]|new[13]	_	_
3-12	230-233	and	substance[12]	new[12]	_	_
3-13	234-239	exert	substance[12]	new[12]	_	_
3-14	240-250	biological	substance[12]|abstract[14]	new[12]|new[14]	coref	18-16[134_14]
3-15	251-258	effects	substance[12]|abstract[14]	new[12]|new[14]	_	_
3-16	259-260	.	_	_	_	_

#Text=The microbiota also impacts on the integrity of the gut barrier .
4-1	261-264	The	abstract[15]	giv[15]	coref	6-8[29_15]
4-2	265-275	microbiota	abstract[15]	giv[15]	_	_
4-3	276-280	also	_	_	_	_
4-4	281-288	impacts	_	_	_	_
4-5	289-291	on	_	_	_	_
4-6	292-295	the	abstract[16]	new[16]	_	_
4-7	296-305	integrity	abstract[16]	new[16]	_	_
4-8	306-308	of	abstract[16]	new[16]	_	_
4-9	309-312	the	abstract[16]|object[18]	new[16]|giv[18]	coref	5-1[20_18]
4-10	313-316	gut	abstract[16]|abstract|object[18]	new[16]|giv|giv[18]	coref	9-35
4-11	317-324	barrier	abstract[16]|object[18]	new[16]|giv[18]	_	_
4-12	325-326	.	_	_	_	_

#Text=Gut barrier dysfunction may result in bacterial translocation from the intestines with increased plasma lipopolysaccharides ( LPS ) .
5-1	327-330	Gut	person|object[20]|abstract[21]	new|giv[20]|new[21]	coref	7-1
5-2	331-338	barrier	object[20]|abstract[21]	giv[20]|new[21]	_	_
5-3	339-350	dysfunction	abstract[21]	new[21]	_	_
5-4	351-354	may	_	_	_	_
5-5	355-361	result	_	_	_	_
5-6	362-364	in	_	_	_	_
5-7	365-374	bacterial	event[22]	new[22]	_	_
5-8	375-388	translocation	event[22]	new[22]	_	_
5-9	389-393	from	event[22]	new[22]	_	_
5-10	394-397	the	event[22]|place[23]	new[22]|new[23]	_	_
5-11	398-408	intestines	event[22]|place[23]	new[22]|new[23]	_	_
5-12	409-413	with	event[22]	new[22]	_	_
5-13	414-423	increased	event[22]|substance[25]	new[22]|new[25]	_	_
5-14	424-430	plasma	event[22]|abstract|substance[25]	new[22]|new|new[25]	_	_
5-15	431-450	lipopolysaccharides	event[22]|substance[25]	new[22]|new[25]	_	_
5-16	451-452	(	_	_	_	_
5-17	453-456	LPS	abstract	new	_	_
5-18	457-458	)	_	_	_	_
5-19	459-460	.	_	_	_	_

#Text=Multiple studies have found a relationship between the microbiota and adequate metabolic , hormonal and immunologic homeostasis .
6-1	461-469	Multiple	abstract[27]	new[27]	_	_
6-2	470-477	studies	abstract[27]	new[27]	_	_
6-3	478-482	have	_	_	_	_
6-4	483-488	found	_	_	_	_
6-5	489-490	a	abstract[28]	new[28]	_	_
6-6	491-503	relationship	abstract[28]	new[28]	_	_
6-7	504-511	between	abstract[28]	new[28]	_	_
6-8	512-515	the	abstract[28]|abstract[29]	new[28]|giv[29]	coref	7-10[34_29]
6-9	516-526	microbiota	abstract[28]|abstract[29]	new[28]|giv[29]	_	_
6-10	527-530	and	abstract[28]	new[28]	_	_
6-11	531-539	adequate	abstract[28]|abstract[30]	new[28]|new[30]	coref	14-7[105_30]
6-12	540-549	metabolic	abstract[28]|abstract[30]	new[28]|new[30]	_	_
6-13	550-551	,	abstract[28]|abstract[30]	new[28]|new[30]	_	_
6-14	552-560	hormonal	abstract[28]|abstract[30]	new[28]|new[30]	_	_
6-15	561-564	and	abstract[28]|abstract[30]	new[28]|new[30]	_	_
6-16	565-576	immunologic	abstract[28]|abstract[30]	new[28]|new[30]	_	_
6-17	577-588	homeostasis	abstract[28]|abstract[30]	new[28]|new[30]	_	_
6-18	589-590	.	_	_	_	_

#Text=Gut dysbiosis , i.e. , an altered composition of the intestinal microbiota in disease is associated with poor health outcomes .
7-1	591-594	Gut	person|abstract[32]	giv|new[32]	appos	7-4[33_32]
7-2	595-604	dysbiosis	abstract[32]	new[32]	_	_
7-3	605-606	,	_	_	_	_
7-4	607-611	i.e.	abstract[33]	giv[33]	coref	8-1[0_33]
7-5	612-613	,	abstract[33]	giv[33]	_	_
7-6	614-616	an	abstract[33]	giv[33]	_	_
7-7	617-624	altered	abstract[33]	giv[33]	_	_
7-8	625-636	composition	abstract[33]	giv[33]	_	_
7-9	637-639	of	abstract[33]	giv[33]	_	_
7-10	640-643	the	abstract[33]|abstract[34]	giv[33]|giv[34]	coref	8-23[45_34]
7-11	644-654	intestinal	abstract[33]|abstract[34]	giv[33]|giv[34]	_	_
7-12	655-665	microbiota	abstract[33]|abstract[34]	giv[33]|giv[34]	_	_
7-13	666-668	in	abstract[33]	giv[33]	_	_
7-14	669-676	disease	abstract[33]|abstract	giv[33]|new	_	_
7-15	677-679	is	_	_	_	_
7-16	680-690	associated	_	_	_	_
7-17	691-695	with	_	_	_	_
7-18	696-700	poor	abstract[37]	new[37]	_	_
7-19	701-707	health	abstract|abstract[37]	new|new[37]	_	_
7-20	708-716	outcomes	abstract[37]	new[37]	_	_
7-21	717-718	.	_	_	_	_

#Text=Dysbiosis may be treated with probiotics , i.e. , live strains of selected bacteria , or prebiotics , food components that modulate the microbiota .
8-1	719-728	Dysbiosis	abstract	giv	coref	10-1
8-2	729-732	may	_	_	_	_
8-3	733-735	be	_	_	_	_
8-4	736-743	treated	_	_	_	_
8-5	744-748	with	_	_	_	_
8-6	749-759	probiotics	object	new	_	_
8-7	760-761	,	_	_	_	_
8-8	762-766	i.e.	plant[40]	new[40]	_	_
8-9	767-768	,	plant[40]	new[40]	_	_
8-10	769-773	live	plant[40]	new[40]	_	_
8-11	774-781	strains	plant[40]	new[40]	_	_
8-12	782-784	of	plant[40]	new[40]	_	_
8-13	785-793	selected	plant[40]|animal[41]	new[40]|giv[41]	coref	10-43[65_41]
8-14	794-802	bacteria	plant[40]|animal[41]	new[40]|giv[41]	_	_
8-15	803-804	,	_	_	_	_
8-16	805-807	or	_	_	_	_
8-17	808-818	prebiotics	substance	new	appos	8-19[44_0]
8-18	819-820	,	_	_	_	_
8-19	821-825	food	object|substance[44]	new|giv[44]	_	_
8-20	826-836	components	substance[44]	giv[44]	_	_
8-21	837-841	that	substance[44]	giv[44]	_	_
8-22	842-850	modulate	substance[44]	giv[44]	_	_
8-23	851-854	the	substance[44]|abstract[45]	giv[44]|giv[45]	coref	9-34[51_45]
8-24	855-865	microbiota	substance[44]|abstract[45]	giv[44]|giv[45]	_	_
8-25	866-867	.	_	_	_	_

#Text=Multiple metabolic , cardiovascular , and respiratory diseases including type 2 diabetes mellitus , obesity , systemic and pulmonary hypertension , atherosclerosis , heart failure and chronic respiratory diseases have been linked to impaired gut microbiota .
9-1	868-876	Multiple	abstract[46]	new[46]	coref	15-13[118_46]
9-2	877-886	metabolic	abstract[46]	new[46]	_	_
9-3	887-888	,	abstract[46]	new[46]	_	_
9-4	889-903	cardiovascular	abstract[46]	new[46]	_	_
9-5	904-905	,	abstract[46]	new[46]	_	_
9-6	906-909	and	abstract[46]	new[46]	_	_
9-7	910-921	respiratory	abstract[46]	new[46]	_	_
9-8	922-930	diseases	abstract[46]	new[46]	_	_
9-9	931-940	including	abstract[46]	new[46]	_	_
9-10	941-945	type	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-11	946-947	2	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-12	948-956	diabetes	abstract[46]|abstract[47]|abstract	new[46]|new[47]|new	_	_
9-13	957-965	mellitus	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-14	966-967	,	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-15	968-975	obesity	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-16	976-977	,	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-17	978-986	systemic	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-18	987-990	and	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-19	991-1000	pulmonary	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-20	1001-1013	hypertension	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-21	1014-1015	,	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-22	1016-1031	atherosclerosis	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-23	1032-1033	,	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-24	1034-1039	heart	abstract[46]|abstract[47]|object	new[46]|new[47]|new	_	_
9-25	1040-1047	failure	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-26	1048-1051	and	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-27	1052-1059	chronic	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-28	1060-1071	respiratory	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-29	1072-1080	diseases	abstract[46]|abstract[47]	new[46]|new[47]	_	_
9-30	1081-1085	have	_	_	_	_
9-31	1086-1090	been	_	_	_	_
9-32	1091-1097	linked	_	_	_	_
9-33	1098-1100	to	_	_	_	_
9-34	1101-1109	impaired	abstract[51]	giv[51]	coref	19-12[144_51]
9-35	1110-1113	gut	abstract|abstract[51]	giv|giv[51]	coref	19-13
9-36	1114-1124	microbiota	abstract[51]	giv[51]	_	_
9-37	1125-1126	.	_	_	_	_

#Text=Dysbiosis is frequently characterized by : ( a ) lower microbial diversity and richness , ( b ) changes in the relative abundance of phyla with an increased Firmicutes to Bacteroidetes ratio ( F/B ) , and ( c ) changes in short chain fatty acids ( SCFA ) producing bacteria with a relative increase in lactate-producing bacteria and a relative decrease in acetate- and butyrate-producing bacteria .
10-1	1127-1136	Dysbiosis	abstract	giv	_	_
10-2	1137-1139	is	_	_	_	_
10-3	1140-1150	frequently	_	_	_	_
10-4	1151-1164	characterized	_	_	_	_
10-5	1165-1167	by	_	_	_	_
10-6	1168-1169	:	_	_	_	_
10-7	1170-1171	(	_	_	_	_
10-8	1172-1173	a	_	_	_	_
10-9	1174-1175	)	_	_	_	_
10-10	1176-1181	lower	abstract[53]	new[53]	_	_
10-11	1182-1191	microbial	abstract[53]	new[53]	_	_
10-12	1192-1201	diversity	abstract[53]	new[53]	_	_
10-13	1202-1205	and	_	_	_	_
10-14	1206-1214	richness	abstract[54]	new[54]	_	_
10-15	1215-1216	,	abstract[54]	new[54]	_	_
10-16	1217-1218	(	abstract[54]	new[54]	_	_
10-17	1219-1220	b	abstract[54]	new[54]	_	_
10-18	1221-1222	)	abstract[54]	new[54]	_	_
10-19	1223-1230	changes	event[55]	new[55]	coref	19-10[142_55]
10-20	1231-1233	in	event[55]	new[55]	_	_
10-21	1234-1237	the	event[55]|abstract[56]	new[55]|new[56]	_	_
10-22	1238-1246	relative	event[55]|abstract[56]	new[55]|new[56]	_	_
10-23	1247-1256	abundance	event[55]|abstract[56]	new[55]|new[56]	_	_
10-24	1257-1259	of	event[55]|abstract[56]	new[55]|new[56]	_	_
10-25	1260-1265	phyla	event[55]|abstract[56]|abstract	new[55]|new[56]|new	_	_
10-26	1266-1270	with	event[55]|abstract[56]	new[55]|new[56]	_	_
10-27	1271-1273	an	event[55]|abstract[56]|abstract[60]	new[55]|new[56]|new[60]	appos	10-34[0_60]
10-28	1274-1283	increased	event[55]|abstract[56]|abstract[60]	new[55]|new[56]|new[60]	_	_
10-29	1284-1294	Firmicutes	event[55]|abstract[56]|abstract[58]|abstract[60]	new[55]|new[56]|new[58]|new[60]	_	_
10-30	1295-1297	to	event[55]|abstract[56]|abstract[58]|abstract[60]	new[55]|new[56]|new[58]|new[60]	_	_
10-31	1298-1311	Bacteroidetes	event[55]|abstract[56]|abstract[58]|abstract|abstract[60]	new[55]|new[56]|new[58]|new|new[60]	_	_
10-32	1312-1317	ratio	event[55]|abstract[56]|abstract[60]	new[55]|new[56]|new[60]	_	_
10-33	1318-1319	(	_	_	_	_
10-34	1320-1323	F/B	abstract	giv	_	_
10-35	1324-1325	)	_	_	_	_
10-36	1326-1327	,	_	_	_	_
10-37	1328-1331	and	_	_	_	_
10-38	1332-1333	(	_	_	_	_
10-39	1334-1335	c	_	_	_	_
10-40	1336-1337	)	_	_	_	_
10-41	1338-1345	changes	abstract[62]	new[62]	_	_
10-42	1346-1348	in	abstract[62]	new[62]	_	_
10-43	1349-1354	short	abstract[62]|substance[64]|animal[65]	new[62]|new[64]|giv[65]	coref	10-57[67_65]
10-44	1355-1360	chain	abstract[62]|substance[64]|animal[65]	new[62]|new[64]|giv[65]	_	_
10-45	1361-1366	fatty	abstract[62]|abstract|substance[64]|animal[65]	new[62]|new|new[64]|giv[65]	_	_
10-46	1367-1372	acids	abstract[62]|substance[64]|animal[65]	new[62]|new[64]|giv[65]	_	_
10-47	1373-1374	(	abstract[62]|animal[65]	new[62]|giv[65]	_	_
10-48	1375-1379	SCFA	abstract[62]|animal[65]	new[62]|giv[65]	_	_
10-49	1380-1381	)	abstract[62]|animal[65]	new[62]|giv[65]	_	_
10-50	1382-1391	producing	abstract[62]|animal[65]	new[62]|giv[65]	_	_
10-51	1392-1400	bacteria	abstract[62]|animal[65]	new[62]|giv[65]	_	_
10-52	1401-1405	with	abstract[62]	new[62]	_	_
10-53	1406-1407	a	abstract[62]|abstract[66]	new[62]|new[66]	_	_
10-54	1408-1416	relative	abstract[62]|abstract[66]	new[62]|new[66]	_	_
10-55	1417-1425	increase	abstract[62]|abstract[66]	new[62]|new[66]	_	_
10-56	1426-1428	in	abstract[62]|abstract[66]	new[62]|new[66]	_	_
10-57	1429-1446	lactate-producing	abstract[62]|abstract[66]|animal[67]	new[62]|new[66]|giv[67]	coref	10-64[70_67]
10-58	1447-1455	bacteria	abstract[62]|abstract[66]|animal[67]	new[62]|new[66]|giv[67]	_	_
10-59	1456-1459	and	abstract[62]	new[62]	_	_
10-60	1460-1461	a	abstract[62]|event[68]	new[62]|new[68]	_	_
10-61	1462-1470	relative	abstract[62]|event[68]	new[62]|new[68]	_	_
10-62	1471-1479	decrease	abstract[62]|event[68]	new[62]|new[68]	_	_
10-63	1480-1482	in	abstract[62]|event[68]	new[62]|new[68]	_	_
10-64	1483-1491	acetate-	abstract[62]|event[68]|substance|animal[70]	new[62]|new[68]|new|giv[70]	_	_
10-65	1492-1495	and	abstract[62]|event[68]|animal[70]	new[62]|new[68]|giv[70]	_	_
10-66	1496-1514	butyrate-producing	abstract[62]|event[68]|animal[70]	new[62]|new[68]|giv[70]	_	_
10-67	1515-1523	bacteria	abstract[62]|event[68]|animal[70]	new[62]|new[68]|giv[70]	_	_
10-68	1524-1525	.	_	_	_	_

#Text=Vitamin D is produced from dermal exposure to sunlight or from the diet and is converted in the liver into 25-OH-cholecaciferol or calcifediol ( 25OHVitD ) , whose measure serves as an indicator of the vitamin D status .
11-1	1526-1533	Vitamin	substance	new	coref	11-36[82_0]
11-2	1534-1535	D	person	new	coref	12-25
11-3	1536-1538	is	_	_	_	_
11-4	1539-1547	produced	_	_	_	_
11-5	1548-1552	from	_	_	_	_
11-6	1553-1559	dermal	event[73]	new[73]	coref	13-17[99_73]
11-7	1560-1568	exposure	event[73]	new[73]	_	_
11-8	1569-1571	to	event[73]	new[73]	_	_
11-9	1572-1580	sunlight	event[73]|substance	new[73]|new	_	_
11-10	1581-1583	or	_	_	_	_
11-11	1584-1588	from	_	_	_	_
11-12	1589-1592	the	substance[75]	new[75]	_	_
11-13	1593-1597	diet	substance[75]	new[75]	_	_
11-14	1598-1601	and	_	_	_	_
11-15	1602-1604	is	_	_	_	_
11-16	1605-1614	converted	_	_	_	_
11-17	1615-1617	in	_	_	_	_
11-18	1618-1621	the	object[76]	new[76]	_	_
11-19	1622-1627	liver	object[76]	new[76]	_	_
11-20	1628-1632	into	_	_	_	_
11-21	1633-1653	25-OH-cholecaciferol	abstract	new	_	_
11-22	1654-1656	or	_	_	_	_
11-23	1657-1668	calcifediol	substance	new	appos	11-25
11-24	1669-1670	(	_	_	_	_
11-25	1671-1679	25OHVitD	substance	giv	ana	12-1
11-26	1680-1681	)	_	_	_	_
11-27	1682-1683	,	_	_	_	_
11-28	1684-1689	whose	abstract[80]	new[80]	_	_
11-29	1690-1697	measure	abstract[80]	new[80]	_	_
11-30	1698-1704	serves	_	_	_	_
11-31	1705-1707	as	_	_	_	_
11-32	1708-1710	an	abstract[81]	new[81]	_	_
11-33	1711-1720	indicator	abstract[81]	new[81]	_	_
11-34	1721-1723	of	abstract[81]	new[81]	_	_
11-35	1724-1727	the	abstract[81]|abstract[83]	new[81]|new[83]	_	_
11-36	1728-1735	vitamin	abstract[81]|substance[82]|abstract[83]	new[81]|giv[82]|new[83]	coref	12-24[0_82]
11-37	1736-1737	D	abstract[81]|substance[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
11-38	1738-1744	status	abstract[81]|abstract[83]	new[81]|new[83]	_	_
11-39	1745-1746	.	_	_	_	_

#Text=This is further metabolized mainly in the kidney into 1-α,25-dihydroxycholecalciferol , the most active form , also named calcitriol , which activates the vitamin D receptor ( VDR ) .
12-1	1747-1751	This	substance	giv	_	_
12-2	1752-1754	is	_	_	_	_
12-3	1755-1762	further	_	_	_	_
12-4	1763-1774	metabolized	_	_	_	_
12-5	1775-1781	mainly	_	_	_	_
12-6	1782-1784	in	_	_	_	_
12-7	1785-1788	the	place[85]	new[85]	_	_
12-8	1789-1795	kidney	place[85]	new[85]	_	_
12-9	1796-1800	into	_	_	_	_
12-10	1801-1832	1-α,25-dihydroxycholecalciferol	substance	new	appos	12-12[87_0]
12-11	1833-1834	,	_	_	_	_
12-12	1835-1838	the	substance[87]	giv[87]	_	_
12-13	1839-1843	most	substance[87]	giv[87]	_	_
12-14	1844-1850	active	substance[87]	giv[87]	_	_
12-15	1851-1855	form	substance[87]	giv[87]	_	_
12-16	1856-1857	,	substance[87]	giv[87]	_	_
12-17	1858-1862	also	substance[87]	giv[87]	_	_
12-18	1863-1868	named	substance[87]	giv[87]	_	_
12-19	1869-1879	calcitriol	substance[87]|substance	giv[87]|new	coref	16-9
12-20	1880-1881	,	substance[87]	giv[87]	_	_
12-21	1882-1887	which	substance[87]	giv[87]	_	_
12-22	1888-1897	activates	substance[87]	giv[87]	_	_
12-23	1898-1901	the	substance[87]|abstract[91]	giv[87]|new[91]	appos	12-28[0_91]
12-24	1902-1909	vitamin	substance[87]|substance|abstract[91]	giv[87]|giv|new[91]	coref	13-1
12-25	1910-1911	D	substance[87]|person|abstract[91]	giv[87]|giv|new[91]	coref	13-2
12-26	1912-1920	receptor	substance[87]|abstract[91]	giv[87]|new[91]	_	_
12-27	1921-1922	(	_	_	_	_
12-28	1923-1926	VDR	abstract	giv	coref	16-12
12-29	1927-1928	)	_	_	_	_
12-30	1929-1930	.	_	_	_	_

#Text=Vitamin D deficiency , which causes rickets and osteomalacia , is very common worldwide due to insufficient solar light exposure and/or a reduced dietary intake .
13-1	1931-1938	Vitamin	substance|abstract[95]	giv|new[95]	coref|coref	14-13|15-1[115_95]
13-2	1939-1940	D	person|abstract[95]	giv|new[95]	coref	14-14
13-3	1941-1951	deficiency	abstract[95]	new[95]	_	_
13-4	1952-1953	,	abstract[95]	new[95]	_	_
13-5	1954-1959	which	abstract[95]	new[95]	_	_
13-6	1960-1966	causes	abstract[95]	new[95]	_	_
13-7	1967-1974	rickets	abstract[95]|abstract	new[95]|new	_	_
13-8	1975-1978	and	abstract[95]	new[95]	_	_
13-9	1979-1991	osteomalacia	abstract[95]|abstract	new[95]|new	_	_
13-10	1992-1993	,	_	_	_	_
13-11	1994-1996	is	_	_	_	_
13-12	1997-2001	very	_	_	_	_
13-13	2002-2008	common	_	_	_	_
13-14	2009-2018	worldwide	_	_	_	_
13-15	2019-2022	due	_	_	_	_
13-16	2023-2025	to	_	_	_	_
13-17	2026-2038	insufficient	event[99]	giv[99]	_	_
13-18	2039-2044	solar	abstract[98]|event[99]	new[98]|giv[99]	_	_
13-19	2045-2050	light	abstract[98]|event[99]	new[98]|giv[99]	_	_
13-20	2051-2059	exposure	event[99]	giv[99]	_	_
13-21	2060-2066	and/or	_	_	_	_
13-22	2067-2068	a	abstract[101]	new[101]	_	_
13-23	2069-2076	reduced	abstract[101]	new[101]	_	_
13-24	2077-2084	dietary	substance|abstract[101]	new|new[101]	_	_
13-25	2085-2091	intake	abstract[101]	new[101]	_	_
13-26	2092-2093	.	_	_	_	_

#Text=Besides this well-known regulatory role in the calcium-phosphorus and bone homeostasis , vitamin D is also involved in the control of other physiological processes , such as cellular growth , intracellular metabolism and innate and adaptive immunity .
14-1	2094-2101	Besides	_	_	_	_
14-2	2102-2106	this	abstract[102]	new[102]	_	_
14-3	2107-2117	well-known	abstract[102]	new[102]	_	_
14-4	2118-2128	regulatory	abstract[102]	new[102]	_	_
14-5	2129-2133	role	abstract[102]	new[102]	_	_
14-6	2134-2136	in	abstract[102]	new[102]	_	_
14-7	2137-2140	the	abstract[102]|abstract[105]	new[102]|giv[105]	_	_
14-8	2141-2159	calcium-phosphorus	abstract[102]|substance|abstract[105]	new[102]|new|giv[105]	_	_
14-9	2160-2163	and	abstract[102]|abstract[105]	new[102]|giv[105]	_	_
14-10	2164-2168	bone	abstract[102]|object|abstract[105]	new[102]|new|giv[105]	_	_
14-11	2169-2180	homeostasis	abstract[102]|abstract[105]	new[102]|giv[105]	_	_
14-12	2181-2182	,	_	_	_	_
14-13	2183-2190	vitamin	substance	giv	coref	15-1
14-14	2191-2192	D	person	giv	coref	15-1[114_0]
14-15	2193-2195	is	_	_	_	_
14-16	2196-2200	also	_	_	_	_
14-17	2201-2209	involved	_	_	_	_
14-18	2210-2212	in	_	_	_	_
14-19	2213-2216	the	abstract[108]	new[108]	_	_
14-20	2217-2224	control	abstract[108]	new[108]	_	_
14-21	2225-2227	of	abstract[108]	new[108]	_	_
14-22	2228-2233	other	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-23	2234-2247	physiological	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-24	2248-2257	processes	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-25	2258-2259	,	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-26	2260-2264	such	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-27	2265-2267	as	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-28	2268-2276	cellular	abstract[108]|abstract[109]|event[110]	new[108]|new[109]|new[110]	_	_
14-29	2277-2283	growth	abstract[108]|abstract[109]|event[110]	new[108]|new[109]|new[110]	_	_
14-30	2284-2285	,	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-31	2286-2299	intracellular	abstract[108]|abstract[109]|abstract[111]	new[108]|new[109]|new[111]	_	_
14-32	2300-2310	metabolism	abstract[108]|abstract[109]|abstract[111]	new[108]|new[109]|new[111]	_	_
14-33	2311-2314	and	abstract[108]|abstract[109]	new[108]|new[109]	_	_
14-34	2315-2321	innate	abstract[108]|abstract[109]|abstract[112]	new[108]|new[109]|new[112]	_	_
14-35	2322-2325	and	abstract[108]|abstract[109]|abstract[112]	new[108]|new[109]|new[112]	_	_
14-36	2326-2334	adaptive	abstract[108]|abstract[109]|abstract[112]	new[108]|new[109]|new[112]	_	_
14-37	2335-2343	immunity	abstract[108]|abstract[109]|abstract[112]	new[108]|new[109]|new[112]	_	_
14-38	2344-2345	.	_	_	_	_

#Text=Vitamin D deficiency has also been related to infection , cancer and respiratory and cardiovascular diseases .
15-1	2346-2353	Vitamin	substance|person[114]|abstract[115]	giv|giv[114]|giv[115]	coref|coref|coref	17-3|17-4[0_114]|19-4[139_115]
15-2	2354-2355	D	person[114]|abstract[115]	giv[114]|giv[115]	_	_
15-3	2356-2366	deficiency	abstract[115]	giv[115]	_	_
15-4	2367-2370	has	_	_	_	_
15-5	2371-2375	also	_	_	_	_
15-6	2376-2380	been	_	_	_	_
15-7	2381-2388	related	_	_	_	_
15-8	2389-2391	to	_	_	_	_
15-9	2392-2401	infection	event	new	_	_
15-10	2402-2403	,	_	_	_	_
15-11	2404-2410	cancer	abstract	new	_	_
15-12	2411-2414	and	_	_	_	_
15-13	2415-2426	respiratory	abstract[118]	giv[118]	_	_
15-14	2427-2430	and	abstract[118]	giv[118]	_	_
15-15	2431-2445	cardiovascular	abstract[118]	giv[118]	_	_
15-16	2446-2454	diseases	abstract[118]	giv[118]	_	_
15-17	2455-2456	.	_	_	_	_

#Text=Immune cells and peripheral tissues can also synthetize calcitriol and express VDR .
16-1	2457-2463	Immune	plant[119]	new[119]	_	_
16-2	2464-2469	cells	plant[119]	new[119]	_	_
16-3	2470-2473	and	_	_	_	_
16-4	2474-2484	peripheral	object[120]	new[120]	_	_
16-5	2485-2492	tissues	object[120]	new[120]	_	_
16-6	2493-2496	can	_	_	_	_
16-7	2497-2501	also	_	_	_	_
16-8	2502-2512	synthetize	_	_	_	_
16-9	2513-2523	calcitriol	substance	giv	_	_
16-10	2524-2527	and	_	_	_	_
16-11	2528-2535	express	_	_	_	_
16-12	2536-2539	VDR	abstract	giv	_	_
16-13	2540-2541	.	_	_	_	_

#Text=Thus , vitamin D has been proposed to have immunomodulatory properties and insufficient vitamin D levels may lead to dysregulation of immune responses .
17-1	2542-2546	Thus	_	_	_	_
17-2	2547-2548	,	_	_	_	_
17-3	2549-2556	vitamin	substance	giv	coref	17-14
17-4	2557-2558	D	person	giv	coref	17-14[127_0]
17-5	2559-2562	has	_	_	_	_
17-6	2563-2567	been	_	_	_	_
17-7	2568-2576	proposed	_	_	_	_
17-8	2577-2579	to	_	_	_	_
17-9	2580-2584	have	_	_	_	_
17-10	2585-2601	immunomodulatory	abstract[125]	new[125]	_	_
17-11	2602-2612	properties	abstract[125]	new[125]	_	_
17-12	2613-2616	and	_	_	_	_
17-13	2617-2629	insufficient	abstract[128]	new[128]	_	_
17-14	2630-2637	vitamin	substance|person[127]|abstract[128]	giv|giv[127]|new[128]	coref|coref	18-3[131_0]|19-7[141_127]
17-15	2638-2639	D	person[127]|abstract[128]	giv[127]|new[128]	_	_
17-16	2640-2646	levels	abstract[128]	new[128]	_	_
17-17	2647-2650	may	_	_	_	_
17-18	2651-2655	lead	_	_	_	_
17-19	2656-2658	to	_	_	_	_
17-20	2659-2672	dysregulation	event[129]	new[129]	_	_
17-21	2673-2675	of	event[129]	new[129]	_	_
17-22	2676-2682	immune	event[129]|abstract[130]	new[129]|new[130]	_	_
17-23	2683-2692	responses	event[129]|abstract[130]	new[129]|new[130]	_	_
17-24	2693-2694	.	_	_	_	_

#Text=Moreover , vitamin D is able to induce the expression of antibacterial proteins and exert antibiotic effects in a variety of cell types .
18-1	2695-2703	Moreover	_	_	_	_
18-2	2704-2705	,	_	_	_	_
18-3	2706-2713	vitamin	substance[131]	giv[131]	coref	19-7[0_131]
18-4	2714-2715	D	substance[131]	giv[131]	_	_
18-5	2716-2718	is	_	_	_	_
18-6	2719-2723	able	_	_	_	_
18-7	2724-2726	to	_	_	_	_
18-8	2727-2733	induce	_	_	_	_
18-9	2734-2737	the	abstract[132]	new[132]	_	_
18-10	2738-2748	expression	abstract[132]	new[132]	_	_
18-11	2749-2751	of	abstract[132]	new[132]	_	_
18-12	2752-2765	antibacterial	abstract[132]|substance[133]	new[132]|new[133]	_	_
18-13	2766-2774	proteins	abstract[132]|substance[133]	new[132]|new[133]	_	_
18-14	2775-2778	and	_	_	_	_
18-15	2779-2784	exert	_	_	_	_
18-16	2785-2795	antibiotic	abstract[134]	giv[134]	_	_
18-17	2796-2803	effects	abstract[134]	giv[134]	_	_
18-18	2804-2806	in	_	_	_	_
18-19	2807-2808	a	abstract[135]	new[135]	_	_
18-20	2809-2816	variety	abstract[135]	new[135]	_	_
18-21	2817-2819	of	abstract[135]	new[135]	_	_
18-22	2820-2824	cell	abstract[135]|object|place[137]	new[135]|new|new[137]	_	_
18-23	2825-2830	types	abstract[135]|place[137]	new[135]|new[137]	_	_
18-24	2831-2832	.	_	_	_	_

#Text=We hypothesized that a deficiency in vitamin D induces changes in the gut microbiota .
19-1	2833-2835	We	person	acc	_	_
19-2	2836-2848	hypothesized	_	_	_	_
19-3	2849-2853	that	_	_	_	_
19-4	2854-2855	a	abstract[139]	giv[139]	_	_
19-5	2856-2866	deficiency	abstract[139]	giv[139]	_	_
19-6	2867-2869	in	abstract[139]	giv[139]	_	_
19-7	2870-2877	vitamin	abstract[139]|substance|person[141]	giv[139]|giv|giv[141]	_	_
19-8	2878-2879	D	abstract[139]|person[141]	giv[139]|giv[141]	_	_
19-9	2880-2887	induces	_	_	_	_
19-10	2888-2895	changes	event[142]	giv[142]	_	_
19-11	2896-2898	in	event[142]	giv[142]	_	_
19-12	2899-2902	the	event[142]|abstract[144]	giv[142]|giv[144]	_	_
19-13	2903-2906	gut	event[142]|abstract|abstract[144]	giv[142]|giv|giv[144]	_	_
19-14	2907-2917	microbiota	event[142]|abstract[144]	giv[142]|giv[144]	_	_
19-15	2918-2919	.	_	_	_	_
